Question · asked by 1 review
QUETIAPINE vs CLOZAPINE ‐ all data short term: Weight gain
- Population
- schizophrenia
- Intervention
- QUETIAPINE
- Comparison
- CLOZAPINE ‐ all data short term
- Outcome
- Weight gain
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic ‐ weight gain compared with CLOZAPINE ‐ all data short term (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
QUETIAPINE vs CLOZAPINE ‐ all data short term Adverse effects: 3. Metabolic ‐ weight gain · participants with schizophrenia QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic ‐ weight gain compared with CLOZAPINE ‐ all data short term (low certainty). Quetiapine versus other atypical antipsychotics for schizophrenia (2013) · Cochrane Headline outcomes only | RR 0.53 [0.25, 1.11] | 2 studies · 135 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.